Dilated cardiomyopathy is a syndrome characterized by dilatation and impaired function of one or both ventricles and represents the most common heart failure entity requiring heart transplantation. The treatment we currently use does not directly influence specific underlying pathomechanisms of this disorder, and several attempts are being made in order to introduce more specific therapies. We summarized the most important pharmacological strategies that are being evaluated for the treatment of dilated cardiomyopathy and pointed out the novel therapeutic approaches concerning heart failure secondary to this clinical condition.

Download full-text PDF

Source

Publication Analysis

Top Keywords

dilated cardiomyopathy
12
treatment dilated
8
heart failure
8
pharmacological treatment
4
cardiomyopathy dilated
4
cardiomyopathy syndrome
4
syndrome characterized
4
characterized dilatation
4
dilatation impaired
4
impaired function
4

Similar Publications

Background: Dilated cardiomyopathy (DCM) stands as one of the most prevalent and severe causes of heart failure. Inflammation plays a pivotal role throughout the progression of DCM to heart failure, while age acts as a natural predisposing factor for all cardiovascular diseases. These two factors often interact, contributing to cardiac fibrosis, which is both a common manifestation and a pathogenic driver of adverse remodeling in DCM-induced heart failure.

View Article and Find Full Text PDF

Recent development in CRISPR-Cas systems for cardiac disease.

Prog Mol Biol Transl Sci

January 2025

Department of Microbiology, Gargi College, University of Delhi, New Delhi, India. Electronic address:

The CRISPR-Cas system has emerged as a revolutionary tool in genetic research, enabling highly precise gene editing and significantly advancing the field of cardiovascular science. This chapter provides a comprehensive overview of the latest developments in utilizing CRISPR-Cas technologies to investigate and treat heart diseases. It delves into the application of CRISPR-Cas9 for creating accurate models of complex cardiac conditions, such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and various arrhythmias, which are essential for understanding disease mechanisms and testing potential therapies.

View Article and Find Full Text PDF

MnSOD non-acetylation mimic knock-in mice exhibit dilated cardiomyopathy.

Free Radic Biol Med

January 2025

Department of Radiation Oncology, Mays Cancer Center at UT Health San Antonio MD Anderson, Joe R. and Teresa Lozano Long School of Medicine, TX, USA. Electronic address:

Manganese superoxide dismutase (MnSOD/SOD2) is an essential mitochondrial enzyme that detoxifies superoxide radicals generated during oxidative respiration. MnSOD/SOD2 lysine 68 acetylation (K68-Ac) is an important post-translational modification (PTM) that regulates enzymatic activity, responding to nutrient status or oxidative stress, and elevated levels have been associated with human illness. To determine the in vivo role of MnSOD-K68 in the heart, we used a whole-body non-acetylation mimic mutant (MnSOD) knock-in mouse.

View Article and Find Full Text PDF

A 71-year-old woman with dilated cardiomyopathy underwent an echocardiogram showing new onset of multiple mobile left ventricular masses. She experienced a mild COVID-19 infection 1 month before. After a multimodality imaging evaluation, vitamin K antagonist treatment was started, with progressive reduction of the masses without clinical events.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!